Endologix Announces that Scott Ward Joins Board of Directors

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that Scott Ward has been appointed to the Endologix Board of Directors.

Scott Ward was most recently the CEO and Chairman of the Board of Cardiovascular Systems. Over the course of his career, he has served on over 15 public and private company Boards as well as numerous non-profit Boards, including Gillette Children’s where he is currently the Chairman of the Philanthropy Board. Mr. Ward has over 40 years of experience in the healthcare industry, including nearly 30 years at Medtronic, Inc. where he served in various leadership roles including the Senior Vice President and President of the CardioVascular, Neurological and Diabetes businesses. Mr. Ward is the Founder of Raymond Holdings, a firm with activities in venture capital, strategy and transactional advisory services for medical technology and life science companies.

"We are delighted to announce Scott Ward as the newest member of the Endologix Board of Directors," expressed Matt Thompson, MD, President, and CEO of Endologix. "Scott's extensive background in the healthcare sector, highlighted by his tenure at Medtronic and leadership at Cardiovascular Systems, brings an invaluable depth of experience to our team. Scott's expertise in the medical device industry and his commitment to innovation will be pivotal as we forge ahead to advance our product portfolio and the DETOUR System’s full market release."

Mr. Ward expressed his enthusiasm about joining the Endologix Board, stating, “I am honored to be appointed to the Endologix Board of Directors. My four decades in the healthcare industry have shown me the transformative power of innovative medical solutions in patient care. I eagerly anticipate collaborating with the Board and leadership team to advance Endologix's strategic objectives. The Endologix therapeutic portfolio, particularly the DETOUR System with its novel approach to treating complex PAD, stands out as a testament to the company's commitment to patients with vascular disease.” He concluded, “I am committed to leveraging my experience to contribute to the company's dynamic future and the continuous improvement in patient care.”

About Endologix

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix's commercial products, including the AFX®2 Endovascular AAA System, ALTO® Abdominal Stent Graft System, and the DETOUR^TM System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, California. To learn more about Endologix, please visit https://www.endologix.com/.